Analyst Naz Rahman of Maxim Group reiterated a Buy rating on Viking Therapeutics (VKTX – Research Report), retaining the price target of ...

The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $62.45, representing a -0.3% change from its previous close.

Viking Therapeutics has announced positive results from its Phase Ib trial of VK0214 in patients with X-linked ...

Viking Therapeutics (VKTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst ...

Viking Therapeutics Inc. on Wednesday reported positive data from an early-stage trial of a treatment for the rare, and often ...

Viking Therapeutics Inc.'s stock rose 1.4% in premarket trade Wednesday, after the biotech reported positive data from an early-stage trial of a treatment for the rare, and often fatal, metabolic ...

Eli Lilly’s CEO David Ricks is confident his company and peer Novo Nordisk are years ahead in the weight loss space, as ...

It's been a strong day for Viking Therapeutics. Its shares are now trading at $67.11, marking a 6.5% change since the previous market close. An analyst favorite, the Pharmaceutical company has a ...

On Monday, Viking Therapeutics Inc (VKTX) stock saw a decline, ending the day at $63.01 which represents a decrease of $-1.95 or -3.00% from the prior close of $64.96. The stock opened at $65.61 and ...

We recently compiled a list of the 10 Best Hot Stocks To Buy Right Now. In this article, we are going to take a look at where ...

In phase 2, VK2735 reduced patients' weight by about 15% after 13 weeks of treatment and maintained a clean safety profile.